Background: Intravenous immunoglobulin (IVIG) is the mainstay of initial treatment for Kawasaki disease (KD). Previously, 5% immunoglobulin was used for the treatment of patients with KD; however, a 10% immunoglobulin preparation has recently become available.
Purpose: To analyze the safety and effectiveness of treatment with 10% immunoglobulin in patients with KD. Additionally, we sought to determine whether it was possible to shorten the interval between the initial IVIG dose and the second IVIG dose, among the patients who did not respond to the initial IVIG dose (non-responders) in the 10% IVIG group.
Methods: We retrospectively compared the clinical findings of 103 patients who were administered 5% IVIG, and 60 patients who were administered 10% IVIG between January 2015 and May 2019.
Results: The clinical profiles were not significantly different between the 5% and 10% groups. A total of 31 (30%) patients in the 5% group, and 20 (33%) patients in the 10% group, were nonresponsive to the initial IVIG dose, although these differences were not significant (p=0.727). The interval between the initial IVIG dose and the second IVIG dose among the non-responders was significantly shorter in the 10% IVIG group than the 5% IVIG group (48.8 vs 45.4 hours, p=0.004). Only one patient in the 5% group developed coronary artery lesions, and no serious adverse events were observed.
Conclusion: Results showed that 10% immunoglobulin is as safe and effective as 5% immunoglobulin for the treatment of patients with KD, and can provide additional early treatment for non-responders to the initial IVIG dose.
View full abstract